Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women

NCT06315205 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Letrozole LEBE 75 mg
DRUG: Letrozole LEBE 150 mg
DRUG: Letrozole LEBE 225 mg

Sponsor

Rovi Pharmaceuticals Laboratories